comparemela.com

Latest Breaking News On - Terns pharmaceuticals stock performance - Page 1 : comparemela.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month […]

Nasdaq
Vivo-opportunity-llc
Terns-pharmaceuticals-inc
Affinity-asset-advisors
Terns-pharmaceuticals-stock-performance
News-ratings-for-terns-pharmaceuticals-daily
Analyst-recommendations-for-terns-pharmaceuticals
Terns-pharmaceuticals
Insider-transactions-at-terns-pharmaceuticals
Get-free-report
Vivo-opportunity

Terns Pharmaceuticals (NASDAQ:TERN) Earns "Neutral" Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $5.50 target price on the stock. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q2 2024 earnings at ($0.33) EPS, FY2024 earnings at […]

Affinity-asset-advisors
Insider-transactions-at-terns-pharmaceuticals
Terns-pharmaceuticals-stock-performance
Analyst-recommendations-for-terns-pharmaceuticals
Janus-henderson-group
Vivo-opportunity-llc
Terns-pharmaceuticals
News-ratings-for-terns-pharmaceuticals-daily
Walleye-trading
Pricet-rowe-associates-inc
Institutional-investors-weigh-in-on-terns-pharmaceuticals

Terns Pharmaceuticals' (TERN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $5.50 target price on the stock. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q2 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.36) EPS, […]

China
Bleakley-financial-group
Securities-exchange-commission
Vivo-opportunity-llc
Institutional-trading-of-terns-pharmaceuticals
Simplicity-solutions
China-universal-asset-management-co
Terns-pharmaceuticals
Terns-pharmaceuticals-stock-performance
Analyst-recommendations-for-terns-pharmaceuticals
Insider-transactions-at-terns-pharmaceuticals

Terns Pharmaceuticals' (TERN) Neutral Rating Reaffirmed at HC Wainwright

Terns Pharmaceuticals' (TERN) Neutral Rating Reaffirmed at HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Vivo-opportunity-llc
Terns-pharmaceuticals
Terns-pharmaceuticals-inc
Terns-pharmaceuticals-stock-performance
Analyst-recommendations-for-terns-pharmaceuticals
Decheng-capital
Affinity-asset-advisors
Great-point-partners
Institutional-trading-of-terns-pharmaceuticals
Terns-pharmaceuticals-company-profile
News-ratings-for-terns-pharmaceuticals-daily

Terns Pharmaceuticals' (TERN) "Market Outperform" Rating Reaffirmed at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a report issued on Tuesday morning, Benzinga reports. The firm currently has a $15.00 target price on the stock. Several other research analysts have also weighed in on TERN. HC Wainwright reissued a neutral rating and set a […]

China
Institutional-trading-of-terns-pharmaceuticals
Vivo-opportunity-llc
News-ratings-for-terns-pharmaceuticals-daily
Analyst-recommendations-for-terns-pharmaceuticals
Bleakley-financial-group
Nasdaq
Terns-pharmaceuticals
China-universal-asset-management-co
Terns-pharmaceuticals-stock-performance
Terns-pharmaceuticals-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.